The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Stage IIIA Melanoma
Stage IIB Melanoma (Locally Advanced)
Recurrent Melanoma
Stage IIC Melanoma (Locally Advanced)
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma (Limited, Resectable)

Interventions: Drug: dabrafenib
Drug: trametinib
Other: laboratory biomarker analysis

First Posted Date: 2012-10-04

Last Posted Date: 2017-06-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 13

Registration Number: NCT01701037

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Nashville Early Diagnosis Lung Cancer Project

Active, not recruiting

Conditions: Lung Cancer

Interventions: Procedure: Sputum sample
Procedure: Pulmonary function tests
Radiation: Computerized tomography (CT) scan of the chest
Other: Buccal epithelium collection
Procedure: Nasal brushings
Procedure: Bronchoscopy
Procedure: Bronchoalveolar lavage
Procedure: Blood sample collection
Procedure: Urine sample
Procedure: Questionnaire-data collection

First Posted Date: 2011-11-21

Last Posted Date: 2023-12-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 480

Registration Number: NCT01475500

Locations: 🇺🇸
Veterans Administration, Nashville, Tennessee, United States
🇺🇸
Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma

Interventions: Radiation: 68Ga-DOTATATE PET scan

First Posted Date: 2011-07-18

Last Posted Date: 2016-03-29

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 97

Registration Number: NCT01396382

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions: Drug: linifanib

First Posted Date: 2011-06-03

Last Posted Date: 2014-08-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT01365910

Locations: 🇺🇸
Vanderbilt Cool Springs, Franklin, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Not Applicable

Terminated

Conditions: Graft Versus Host Disease (GVHD)

Interventions: Procedure: extracorporeal photopheresis
Other: laboratory biomarker analysis

First Posted Date: 2011-03-29

Last Posted Date: 2021-01-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 85

Registration Number: NCT01324908

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Phase 2

Terminated

Conditions: Stage IIIc Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Other: laboratory biomarker identification and analysis
Procedure: biopsy
Other: immunohistochemistry/tissue microarrays
Genetic: TdT-mediated dUTP nick end labeling assay
Other: mass spectrometry

First Posted Date: 2011-03-16

Last Posted Date: 2016-05-30

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 12

Registration Number: NCT01316692

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Phase 1

Completed

Conditions: Tumors Metastatic to Brain

Interventions: Drug: sorafenib tosylate
Radiation: stereotactic radiosurgery
Other: laboratory biomarker analysis

First Posted Date: 2011-01-13

Last Posted Date: 2017-07-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 23

Registration Number: NCT01276210

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: BEZ235
Drug: BKM 120
Drug: Letrozole
Drug: BKM120

First Posted Date: 2010-11-25

Last Posted Date: 2016-07-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 72

Registration Number: NCT01248494

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Massachusetts General Hospital, Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 3 locations

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Phase 2

Withdrawn

Conditions: Metastatic Breast Cancer

Interventions: Drug: MK-2206
Drug: Exemestane
Drug: Goserelin

First Posted Date: 2010-11-15

Last Posted Date: 2013-08-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT01240941

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Phase 1

Withdrawn

Conditions: Metastatic Breast Cancer

Interventions: Drug: MSK-2206
Drug: Exemestane
Drug: Goserelin

First Posted Date: 2010-11-15

Last Posted Date: 2013-08-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT01240928

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy